.jpeg)
{{ variable.name }}
Eltrombopag drug information compilation
1. Generic name: Eltrombopag
2. Trade name: PR OMACTA®
It is used to treat thrombocytopenia in chronic immune thrombocytopenic purpura (ITP) patients who have an inadequate response to glucocorticoids, immunoglobulins, or splenectomy. Use only in patients with a degree of thrombocytopenia and clinical conditions that increase the risk of bleeding and not in an attempt to normalize platelet counts.
1. 25mg tablet : round.
2. 50mg tablet : round.
Each tablet contains eltrombopag ethanolamine salt (equivalent to 25mg or 50mg eltrombopag free acid).
1. Initial dose of :
Most patients: 50 mg once a day;
East Asian or patients with moderate/severe liver damage: 25 mg once a day.
2. Medication time : Take on an empty stomach (1 hour before a meal or 2 hours after a meal). Avoid taking it with drugs/food containing polyvalent cations (such as iron, calcium, magnesium) (an interval of 4 hours is required).
3. Maximum dose of : no more than 75mg/day.
1. When the platelet count result is <50×10⁹/L (for ≥ 2 weeks, the daily dose should be increased by 25 mg (maximum 75 mg/day))
2. When the platelet count result is When 200-400×10⁹/L, the daily dose should be reduced by 25 mg and evaluated after 2 weeks
3. When the platelet count result is >400×10⁹/L, the medication should be suspended. If the platelet count is <150×10⁹/L, the dose should be reduced by 25 mg and restarted.
4. When the platelet count result is >400×10⁹/L (still occurs at the lowest dose), the drug should be permanently discontinued
1. Dietary contraindications : Avoid taking with dairy products, antacids or mineral supplements (with an interval of 4 hours).
2. Missed dose/vomiting : If you miss a dose, you should take it as soon as you remember (unless it is close to the next dose time); there is no need to take it after vomiting.
3. Monitoring requirements :
Test liver function (ALT/ AST, bilirubin), blood routine (including platelet count and peripheral blood smear).
Platelets need to be monitored for at least 4 weeks after stopping the drug (they may rebound to lower levels).
1. Patients with liver damage : The starting dose of for moderate/severe patients is 25 mg/day, and liver function needs to be closely monitored.
2. U200c for pregnant women: It may cause harm to the fetus, so you need to weigh the pros and cons (registration phone number during pregnancy: 1-888-825-5249).
3. Lactation period : Suspend breastfeeding or discontinue medication.
4. Children/elderly : The safety is not clear, and the elderly need to adjust the dose carefully.
1. Common: nausea (6%), vomiting (4%), heavy menstruation (4%), myalgia (3%), paresthesias (3%), cataracts (3%), elevated ALT/AST (2%).
2. Severe: hepatotoxicity, myelofibrosis, thrombosis/embolism, and aggravation of thrombocytopenia after drug withdrawal.
There are no clear contraindications, but use in thrombocytopenia not caused by ITP (such as myelodysplastic syndrome) should be avoided.
1. OATP1B1 substrate (such as rosuvastatin) : may increase exposure, so the dosage needs to be reduced by 50% and monitored.
2. Multivalent cations (such as iron and calcium) : significantly reduce absorption and require an interval of 4 hours.
If it is not clearly stated, it is recommended to refer to the labeling conditions on the drug packaging (usually room temperature and protected from light).